deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03357627

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma

Sponsor: Calithera Biosciences, Inc

Conditions Lymphoma, Follicular Lymphoma, Large B-cell, Diffuse Lymphoma, Non-Hodgkin
Interventions TAK-659 Venetoclax
Updated 18 times since 2017 Last updated: Feb 6, 2023 Started: Feb 16, 2018 Primary completion: Aug 3, 2021 Completion: Aug 3, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Lymphoma, Follicular and Lymphoma, Large B-cell, Diffuse and is currently completed. Calithera Biosciences, Inc leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Dec 2019 · 13 months · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Mar 2023 · 18 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE1

  5. Sep 2021 — Mar 2023 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Aug 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  6. May 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Dec 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Nov 2018 — Dec 2019 [monthly]

    Recruiting PHASE1

  9. Jul 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  11. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Boston, United States , Dallas, United States , Evanston, United States , Frankfurt am Main, Germany , Harvey, United States , Heidelberg, Germany , Mainz, Germany , Montreal, Canada and 4 more locations